AU2013318283A1 - Dihydropyrrolidino-pyrimidines as kinase inhibitors - Google Patents
Dihydropyrrolidino-pyrimidines as kinase inhibitors Download PDFInfo
- Publication number
- AU2013318283A1 AU2013318283A1 AU2013318283A AU2013318283A AU2013318283A1 AU 2013318283 A1 AU2013318283 A1 AU 2013318283A1 AU 2013318283 A AU2013318283 A AU 2013318283A AU 2013318283 A AU2013318283 A AU 2013318283A AU 2013318283 A1 AU2013318283 A1 AU 2013318283A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- compound
- optionally substituted
- amino
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702981P | 2012-09-19 | 2012-09-19 | |
| US61/702,981 | 2012-09-19 | ||
| PCT/US2013/060032 WO2014047020A1 (en) | 2012-09-19 | 2013-09-17 | Dihydropyrrolidino-pyrimidines as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013318283A1 true AU2013318283A1 (en) | 2015-03-05 |
Family
ID=49274870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013318283A Abandoned AU2013318283A1 (en) | 2012-09-19 | 2013-09-17 | Dihydropyrrolidino-pyrimidines as kinase inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9546173B2 (https=) |
| EP (1) | EP2897961B1 (https=) |
| JP (1) | JP6186440B2 (https=) |
| KR (1) | KR20150056550A (https=) |
| CN (1) | CN104640865B (https=) |
| AU (1) | AU2013318283A1 (https=) |
| BR (1) | BR112015005982A2 (https=) |
| CA (1) | CA2882410A1 (https=) |
| EA (1) | EA201590600A1 (https=) |
| ES (1) | ES2612885T3 (https=) |
| IN (1) | IN2015DN01328A (https=) |
| MX (1) | MX2015003535A (https=) |
| WO (1) | WO2014047020A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2612885T3 (es) * | 2012-09-19 | 2017-05-19 | Novartis Ag | Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa |
| JP7349491B2 (ja) * | 2018-07-12 | 2023-09-22 | ユーシービー バイオファルマ エスアールエル | Ｉｌ－１７モジュレーターとしてのスピロ環状インダン類似体 |
| WO2020243457A1 (en) * | 2019-05-29 | 2020-12-03 | Viogen Biosciences, Llc | Compounds and therapeutic uses thereof |
| CN120247783A (zh) * | 2019-08-01 | 2025-07-04 | 普拉特戈公司 | 晚期糖基化终产物的抑制剂 |
| PH12022551118A1 (en) * | 2019-12-10 | 2023-09-18 | Hoffmann La Roche | New braf inhibitors as paradox breakers |
| PL4073065T3 (pl) | 2019-12-10 | 2025-05-19 | F. Hoffmann-La Roche Ag | Nowe pochodne metylochinazolinonu |
| WO2021218912A1 (zh) | 2020-04-30 | 2021-11-04 | 南京明德新药研发有限公司 | 含苯基并内磺酰胺的化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US7208498B2 (en) * | 2002-07-15 | 2007-04-24 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| CA2547080A1 (en) * | 2003-12-02 | 2005-07-28 | Vertex Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors and uses thereof |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| AU2005323797B2 (en) | 2005-01-10 | 2009-07-09 | Pfizer Inc. | Pyrrolopyrazoles, potent kinase inhibitors |
| HRP20110892T1 (hr) | 2005-12-13 | 2011-12-31 | Schering Corporation | Policiklični derivati indazola koji su inhibitori erk |
| AR068046A1 (es) | 2007-06-05 | 2009-11-04 | Schering Corp | Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) * | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| KR20130121122A (ko) | 2010-11-17 | 2013-11-05 | 에프. 호프만-라 로슈 아게 | 종양의 치료 방법 |
| CN103635472B (zh) | 2011-02-28 | 2018-01-12 | 阵列生物制药公司 | 丝氨酸/苏氨酸激酶抑制剂 |
| ES2620612T3 (es) * | 2012-03-02 | 2017-06-29 | Genentech, Inc. | Derivados de sulfóxidos y sulfonas de piridinilo y pirimidinilo |
| ES2612885T3 (es) * | 2012-09-19 | 2017-05-19 | Novartis Ag | Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa |
-
2013
- 2013-09-17 ES ES13771007.5T patent/ES2612885T3/es active Active
- 2013-09-17 US US14/428,546 patent/US9546173B2/en active Active
- 2013-09-17 AU AU2013318283A patent/AU2013318283A1/en not_active Abandoned
- 2013-09-17 BR BR112015005982A patent/BR112015005982A2/pt not_active IP Right Cessation
- 2013-09-17 JP JP2015533126A patent/JP6186440B2/ja active Active
- 2013-09-17 EP EP13771007.5A patent/EP2897961B1/en active Active
- 2013-09-17 KR KR1020157006602A patent/KR20150056550A/ko not_active Withdrawn
- 2013-09-17 CA CA2882410A patent/CA2882410A1/en not_active Abandoned
- 2013-09-17 WO PCT/US2013/060032 patent/WO2014047020A1/en not_active Ceased
- 2013-09-17 CN CN201380048493.XA patent/CN104640865B/zh active Active
- 2013-09-17 EA EA201590600A patent/EA201590600A1/ru unknown
- 2013-09-17 MX MX2015003535A patent/MX2015003535A/es unknown
- 2013-09-17 IN IN1328DEN2015 patent/IN2015DN01328A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2015DN01328A (https=) | 2015-07-03 |
| CN104640865B (zh) | 2018-05-11 |
| MX2015003535A (es) | 2015-07-14 |
| US9546173B2 (en) | 2017-01-17 |
| EA201590600A1 (ru) | 2015-07-30 |
| CN104640865A (zh) | 2015-05-20 |
| ES2612885T3 (es) | 2017-05-19 |
| EP2897961A1 (en) | 2015-07-29 |
| BR112015005982A2 (pt) | 2017-07-04 |
| JP2015529248A (ja) | 2015-10-05 |
| CA2882410A1 (en) | 2014-03-27 |
| JP6186440B2 (ja) | 2017-08-23 |
| WO2014047020A1 (en) | 2014-03-27 |
| KR20150056550A (ko) | 2015-05-26 |
| US20150274733A1 (en) | 2015-10-01 |
| EP2897961B1 (en) | 2016-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3968999B1 (en) | Fgfr inhibitors and methods of use thereof | |
| JP2023071767A (ja) | Ｂｒｍ標的化化合物および関連使用方法 | |
| TW202246255A (zh) | Ｃｄｋ抑制劑及其使用方法 | |
| JP2024532734A (ja) | 複素環式化合物及び使用方法 | |
| AU2016287335B2 (en) | TBK/IKKepsilon inhibitor compounds and uses thereof | |
| JP2021519337A (ja) | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 | |
| KR20210044822A (ko) | 피롤로피리미딘 itk 억제제 | |
| CN121913987A (zh) | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 | |
| EP2897961B1 (en) | Dihydropyrrolidino-pyrimidines as kinase inhibitors | |
| CA3199082A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP2016504990A (ja) | Ｂｅｔタンパク質抑制性ジヒドロピリドピラジノン | |
| JP2018520992A (ja) | アミドで置換されているシクロヘキサン誘導体 | |
| HK1212972A1 (zh) | 作爲bet-蛋白抑制剂用於治疗过度增殖性疾病的吡咯并-和吡唑并-三唑并二氮杂卓 | |
| US20230399327A1 (en) | High activity hpk1 kinase inhibitor | |
| AU2016349148C1 (en) | 1,4-dicarbonyl-piperidyl derivatives | |
| KR20150090044A (ko) | 아자퀴나졸린 카복사미드 유도체 | |
| TW202417458A (zh) | 調節her2的化合物及方法 | |
| CA3154136C (en) | MLL-1 INHIBITORS AND ANTICANCER AGENTS | |
| CA2989684C (en) | Hpk1 inhibitors and methods of using same | |
| HK40091563B (zh) | 嘧啶酮类化合物及其用途 | |
| CN116249696A (zh) | 嘧啶酮类化合物及其用途 | |
| NZ624021B2 (en) | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |